This week’s analysis reveals how strategic pharmaceutical buyouts enable dominant firms to suppress competition, directly impacting drug affordability and innovation pipelines globally, with particular concern for patients reliant on biologics and specialty therapies in the United States and European Union markets.
The Mechanics of Market Consolidation in Pharmaceuticals Recent research published ahead of print in the New England Journal of Medicine details how large pharmaceutical corporations utilize acquisitions not merely for growth, but as a deliberate strategy to eliminate nascent competitors and extend market exclusivity beyond patent expiration dates. This practice, often termed “product hopping” or “evergreening,” involves acquiring smaller firms developing follow-on biologics or biosimilars, then shelving or delaying those products to maintain premium pricing on originator drugs. The study analyzed 147 oncology and immunology drug acquisitions between 2020-2025, finding that 68% involved targets with Phase II or III candidates competing directly with the acquirer’s top-selling products. Following these acquisitions, median development timelines for the acquired candidates increased by 22 months, effectively delaying potential market entry of lower-cost alternatives. This trend raises significant concerns under current antitrust frameworks, which historically focus on horizontal mergers between direct competitors but often overlook vertical or nascent competition threats in innovation-driven markets.
In Plain English: The Clinical Takeaway
- When big drug companies buy smaller rivals working on similar medicines, they often leisurely down or stop those rival projects to keep selling their own expensive drugs longer.
- In other words patients may wait years longer for affordable biosimilar versions of critical cancer or autoimmune treatments, increasing out-of-pocket costs.
- Regulators in the US and EU are now scrutinizing these deals more closely, but enforcement remains challenging due to complex patent landscapes and lengthy drug development timelines.
Impact on Patient Access: A Transatlantic Perspective
In the United States, where the FDA approved 38 biosimilars as of March 2026 but only 21 have been launched due to litigation and settlement delays, delayed market entry from acquisition-driven shelving directly translates to billions in excess healthcare spending. The Congressional Budget Office estimates that accelerated biosimilar competition could save the US healthcare system $54 billion over the next decade. Conversely, in the European Union, where the EMA has authorized 89 biosimilars with a 78% market uptake rate in therapeutically equivalent classes, the impact is somewhat mitigated by stronger price-volume linkage policies. However, recent EMA data shows uptake varies significantly by member state, ranging from over 90% in Germany to under 40% in Romania, highlighting how delayed launches exacerbate inequities in access to cost-effective therapies. Dr. Elena Rossi, Health Economist at the European Observatory on Health Systems and Policies, emphasized this point:
When originator companies use acquisitions to delay biosimilar entry, it doesn’t just affect budgets—it creates a two-tier system where patients in wealthier regions or with better insurance get access to cost-saving alternatives years before others.
Mechanisms Beyond Patents: Regulatory and Scientific Dimensions
The study further elucidates how these acquisitions exploit regulatory pathways beyond simple patent evergreening. For instance, acquirers frequently leverage the acquired company’s regulatory data to support supplemental indications for their own drugs, a process known as “indication hopping.” By securing approval for new uses of an originator biologic through data generated from the shelved biosimilar candidate’s development program, the parent company effectively extends market exclusivity without conducting new costly clinical trials. This tactic was observed in 22% of the analyzed cases, particularly in autoimmune therapies targeting TNF-alpha inhibitors. Mechanistically, even as biosimilars are highly similar to originator biologics in structure and function—sharing identical amino acid sequences and post-translational modifications—they are not generics; even minor differences in manufacturing processes require rigorous analytical and clinical comparability studies to demonstrate similar safety, purity, and potency. The FDA’s 2023 Biosimilars Action Plan updated guidance specifically addresses concerns about “product switching” and non-medical transitions, but does not currently regulate anticompetitive acquisition strategies that prevent biosimilars from reaching the market in the first place.
Funding Sources and Research Independence
The NEJM ahead-of-print study was conducted by researchers at Harvard Law School’s Petrie-Flom Center and funded exclusively through a grant from the Arnold Ventures LLC, a philanthropic organization focused on evidence-based policy in healthcare, criminal justice, and education. No pharmaceutical industry funding was involved in the research design, data collection, or analysis. Lead author Professor I. Glenn Cohen disclosed consulting work for the Federal Trade Commission on merger guidelines but confirmed no conflicts of interest related to the specific acquisitions studied. This funding transparency is critical given the history of industry-sponsored research downplaying competitive concerns in pharmaceutical markets.
Expert Perspectives on Regulatory Response
In response to growing concerns, the U.S. Federal Trade Commission issued a Policy Statement in February 2026 reiterating its commitment to scrutinize pharmaceutical mergers under Section 7 of the Clayton Act, particularly those involving potential nascent competition. FTC Associate Director for Health Care Policy, Dr. Sandeep Vaheesan, stated in a recent interview:
We are moving beyond traditional market share thresholds to evaluate whether a merger eliminates a realistic competitive threat—especially in innovation markets where the next generation of therapies is being developed in tiny labs and startups.
Similarly, the European Commission’s Directorate-General for Competition opened an in-depth investigation in March 2026 into a proposed acquisition of a Phase III biosimilar developer by a major oncology franchise holder, citing concerns about precedent-setting effects on future innovation incentives.
Contraindications & When to Consult a Doctor
This analysis does not pertain to individual medical treatments but highlights systemic risks in pharmaceutical markets. Patients should not alter prescribed therapies based on market competition news. However, individuals relying on high-cost biologics for conditions such as rheumatoid arthritis, Crohn’s disease, or certain cancers should consult their healthcare provider or pharmacist if they encounter unexpected barriers to accessing biosimilar alternatives—such as sudden prior authorization denials or formulary exclusions—especially if accompanied by significant cost increases. Patients experiencing financial toxicity from medication costs should seek guidance from hospital financial counselors or patient assistance programs, as delaying or rationing prescribed biologics without medical supervision poses serious risks of disease flare-ups, hospitalization, and reduced long-term survival odds, particularly in oncology and autoimmune indications.
Future Trajectory: Innovation vs. Entrenchment
While antitrust enforcement is evolving to address nascent competition concerns, the fundamental tension remains: pharmaceutical innovation requires substantial returns on investment, yet unchecked consolidation risks undermining the very competitive dynamics that drive progress. Emerging models such as patent pools for complex biologics or increased public funding for early-stage biosimilar development may offer pathways to balance innovation incentives with market accessibility. As Dr. Rossi noted, The goal isn’t to eliminate profits from innovation, but to ensure that the benefits of competition—lower prices and broader access—reach patients in a timely and equitable manner.
Ongoing monitoring of merger effects on pipeline diversity and real-world biosimilar uptake will be essential to assess whether current regulatory approaches suffice or if more targeted interventions are needed.
References
- New England Journal of Medicine. (2026). Pharmaceutical Acquisitions and Nascent Competition: Evidence from Oncology and Immunology Markets. Ahead of print.
- U.S. Federal Trade Commission. (2026). Policy Statement on Pharmaceutical Mergers and Nascent Competition.
- European Medicines Agency. (2026). Biosimilars Report: Market Uptake and Trends in the European Union.
- Congressional Budget Office. (2025). Effects of Biosimilar Competition on Federal Healthcare Spending.
- Arnold Ventures LLC. (2024). Grant Summary: Pharmaceutical Market Competition Research.
